ReviewProstate international2016
Prostate cancer biomarkers: Are we hitting the mark?
Review in Prostate international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Trial
- Article
- Genomics in active surveillance and post-prostatectomy patients: A review of when and how to use effectively.Current urology reports · 2024Review
- Implementation of multiomic mass spectrometry approaches for the evaluation of human health following environmental exposure.Molecular omics · 2024Review
- Differences in CD24 Expression Between Prostate Adenocarcinoma and Benign Prostatic Hyperplasia: A Cross-sectional Study.Iranian journal of pathology · 2024Article
- Targeted Mass Spectrometry Assays for Specific Quantification of Urinary proPSA Isoforms.Journal of proteome research · 2023Article
- Identification and Validation of FGF-Related Prognostic Signatures in Prostate Cancer.Disease markers · 2023Article
- Evaluating the Role of Morphological Parameters in the Prostate Transition Zone in PHI-Based Predictive Models for Detecting Gray Zone Prostate Cancer.Clinical Medicine Insights. Oncology · 2023Article
- Follow-Up Biomarkers in the Evolution of Prostate Cancer, Levels ofInternational journal of molecular sciences · 2022Article
- Combined miR-486 and GP88 (Progranulin) Serum Levels Are Suggested as Supportive Biomarkers for Therapy Decision in Elderly Prostate Cancer Patients.Life (Basel, Switzerland) · 2022Article
- Mapping genetic variability in mature miRNAs and miRNA binding sites in prostate cancer.Journal of human genetics · 2021Article
- Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study.BMC urology · 2021Observational
- Article
- PSA-based machine learning model improves prostate cancer risk stratification in a screening population.World journal of urology · 2021Article
- Article
- Clinical implications of genomic evaluations for prostate cancer risk stratification, screening, and treatment: a narrative review.Prostate international · 2020Review
- A critical appraisal of biomarkers in prostate cancer.World journal of urology · 2020Review
- MiRNA-Based Inspired Approach in Diagnosis of Prostate Cancer.Medicina (Kaunas, Lithuania) · 2020Review
- Potential Salivary mRNA Biomarkers for Early Detection of Oral Cancer.Journal of clinical medicine · 2020Article
- Preoperative prostate health index and %p2PSA as the significant biomarkers of postoperative pathological outcomes of prostate cancer in Korean males: A prospective multi-institutional study.Investigative and clinical urology · 2020Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLocalised prostate cancer diagnosis and management is increasingly complex due to its heterogeneous progression and prognostic subgroups. Pitfalls in current screening and diagnosis have prompted the search for accurate and invasive molecular and genetic biomarkers for prostate cancer. Such tools may be able to distinguish clinically significant cancers from less aggressive variants to assist with prostate cancer risk stratification and guide decisions and healthcare algorithms. We aimed to provide a comprehensive review of the current prostate cancer biomarkers available and in development.
methodsMEDLINE and EMBASE databases searches were conducted to identify articles pertaining to the use of novel biomarkers for prostate cancer.
resultsA growing number of novel biomarkers are currently under investigation. Such markers include urinary biomarkers, serology-based markers or pathological tissue assessments of molecular and genetic markers. While limited clinical data is present for analysis, early results appear promising. Specifically, a combination of serum and urinary biomarkers (Serum PSA + Urinary PCA3 + Urinary TMPRSS2-ERG fusion) appears to provide superior sensitivity and specificity profiles compared to traditional diagnostic approaches (AUC 0.88).
conclusionThe accurate diagnosis and risk stratification of prostate cancer is critical to ensure appropriate intervention. The development of non-invasive biomarkers can add to the information provided by current screening practices and allows for individualised risk stratification of patients. The use of these biomarkers appears to increase the sensitivity and specificity of diagnosis of prostate cancer. Further studies are necessary to define the appropriate use and time points of each biomarker and their effect on the management algorithm of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.